Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
trastuzumab rezetecan + everolimus
- Development stage
- Unknown
- Lead developer
- Hengrui Pharmaceutical
- Modality
- Small Molecules, Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
- Administration
- Intravenous, Oral
01
Overview
SHR-A1811 + eve is a combination therapy comprising trastuzumab rezetecan (SHR-A1811) and everolimus. Trastuzumab rezetecan is a next-generation antibody-drug conjugate (ADC) targeting HER2, developed by Jiangsu Hengrui Pharmaceuticals. It consists of a humanized anti-HER2 monoclonal antibody (trastuzumab) conjugated via a cleavable tetrapeptide linker to a topoisomerase I inhibitor payload (SHR169265), with a drug-to-antibody ratio (DAR) of 6. Everolimus is a small-molecule inhibitor of the mechanistic target of rapamycin (mTOR). This combination is currently being investigated in a Phase III clinical trial sponsored by Fudan University for the treatment of patients with the Luminal Androgen Receptor (LAR) subtype of triple-negative breast cancer (TNBC), a molecularly distinct subtype that may exhibit low HER2 expression.
- Other names
- trastuzumab rezetecan + everolimus
02
Targets
TOP1 (DNA Topoisomerase I)ERBB2 (Erb-b2 receptor tyrosine kinase 2)
Beyond the preview
Go deeper on trastuzumab rezetecan + everolimus.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on trastuzumab rezetecan + everolimus.